type,targetId,targetName,comparatorId,comparatorName,outcomeId,OutcomeName
Outcome,1,Denosumab,2,ZoledronicAcid,195562,Hemorrhoids
Outcome,1,Denosumab,2,ZoledronicAcid,318736,Migraine
Outcome,1,Denosumab,2,ZoledronicAcid,4090425,Altered sensation of skin
Outcome,1,Denosumab,2,ZoledronicAcid,313459,Sleep apnea
Outcome,1,Denosumab,2,ZoledronicAcid,136661,Non-toxic nodular goiter
Outcome,1,Denosumab,2,ZoledronicAcid,197672,Urinary incontinence
Outcome,1,Denosumab,2,ZoledronicAcid,4209423,Nicotine dependence
Outcome,1,Denosumab,2,ZoledronicAcid,437390,Hypoxemia
Outcome,1,Denosumab,2,ZoledronicAcid,380094,Carpal tunnel syndrome
Outcome,1,Denosumab,2,ZoledronicAcid,377575,Tinnitus
Outcome,1,Denosumab,2,ZoledronicAcid,253796,Pneumothorax
Outcome,1,Denosumab,2,ZoledronicAcid,4214376,Hyperglycemia
Outcome,1,Denosumab,2,ZoledronicAcid,318556,Epistaxis
Outcome,1,Denosumab,2,ZoledronicAcid,434005,Morbid obesity
Outcome,1,Denosumab,2,ZoledronicAcid,432730,Difficulty speaking
Outcome,1,Denosumab,2,ZoledronicAcid,439147,Amnesia
Outcome,1,Denosumab,2,ZoledronicAcid,253797,Post-inflammatory pulmonary fibrosis
Outcome,1,Denosumab,2,ZoledronicAcid,441417,Incoordination
Outcome,1,Denosumab,2,ZoledronicAcid,433454,Adjustment disorder with mixed emotional features
Outcome,1,Denosumab,2,ZoledronicAcid,376065,Neurologic disorder associated with type 2 diabetes mellitus
Outcome,1,Denosumab,2,ZoledronicAcid,4239682,Chronic phototoxic dermatitis
Outcome,1,Denosumab,2,ZoledronicAcid,30133,Acute laryngitis
Outcome,1,Denosumab,2,ZoledronicAcid,73090,Contusion of foot
Outcome,1,Denosumab,2,ZoledronicAcid,137951,Acquired keratoderma
Outcome,1,Denosumab,2,ZoledronicAcid,257683,Posterior rhinorrhea
Outcome,1,Denosumab,2,ZoledronicAcid,137977,Jaundice
Outcome,1,Denosumab,2,ZoledronicAcid,139850,Acute frontal sinusitis
Outcome,1,Denosumab,2,ZoledronicAcid,376229,Abnormal involuntary movement
Outcome,1,Denosumab,2,ZoledronicAcid,193020,Incomplete emptying of bladder
Outcome,1,Denosumab,2,ZoledronicAcid,376382,Tension-type headache
Outcome,1,Denosumab,2,ZoledronicAcid,137063,Corns and callus
Outcome,4,Denosumab,8,ZoledronicAcid,195562,Hemorrhoids
Outcome,4,Denosumab,8,ZoledronicAcid,318736,Migraine
Outcome,4,Denosumab,8,ZoledronicAcid,4090425,Altered sensation of skin
Outcome,4,Denosumab,8,ZoledronicAcid,313459,Sleep apnea
Outcome,4,Denosumab,8,ZoledronicAcid,136661,Non-toxic nodular goiter
Outcome,4,Denosumab,8,ZoledronicAcid,197672,Urinary incontinence
Outcome,4,Denosumab,8,ZoledronicAcid,4209423,Nicotine dependence
Outcome,4,Denosumab,8,ZoledronicAcid,437390,Hypoxemia
Outcome,4,Denosumab,8,ZoledronicAcid,380094,Carpal tunnel syndrome
Outcome,4,Denosumab,8,ZoledronicAcid,377575,Tinnitus
Outcome,4,Denosumab,8,ZoledronicAcid,253796,Pneumothorax
Outcome,4,Denosumab,8,ZoledronicAcid,4214376,Hyperglycemia
Outcome,4,Denosumab,8,ZoledronicAcid,318556,Epistaxis
Outcome,4,Denosumab,8,ZoledronicAcid,434005,Morbid obesity
Outcome,4,Denosumab,8,ZoledronicAcid,432730,Difficulty speaking
Outcome,4,Denosumab,8,ZoledronicAcid,439147,Amnesia
Outcome,4,Denosumab,8,ZoledronicAcid,253797,Post-inflammatory pulmonary fibrosis
Outcome,4,Denosumab,8,ZoledronicAcid,441417,Incoordination
Outcome,4,Denosumab,8,ZoledronicAcid,433454,Adjustment disorder with mixed emotional features
Outcome,4,Denosumab,8,ZoledronicAcid,376065,Neurologic disorder associated with type 2 diabetes mellitus
Outcome,4,Denosumab,8,ZoledronicAcid,4239682,Chronic phototoxic dermatitis
Outcome,4,Denosumab,8,ZoledronicAcid,30133,Acute laryngitis
Outcome,4,Denosumab,8,ZoledronicAcid,73090,Contusion of foot
Outcome,4,Denosumab,8,ZoledronicAcid,137951,Acquired keratoderma
Outcome,4,Denosumab,8,ZoledronicAcid,257683,Posterior rhinorrhea
Outcome,4,Denosumab,8,ZoledronicAcid,137977,Jaundice
Outcome,4,Denosumab,8,ZoledronicAcid,139850,Acute frontal sinusitis
Outcome,4,Denosumab,8,ZoledronicAcid,376229,Abnormal involuntary movement
Outcome,4,Denosumab,8,ZoledronicAcid,193020,Incomplete emptying of bladder
Outcome,4,Denosumab,8,ZoledronicAcid,376382,Tension-type headache
Outcome,4,Denosumab,8,ZoledronicAcid,137063,Corns and callus
Outcome,5,Denosumab,9,ZoledronicAcid,195562,Hemorrhoids
Outcome,5,Denosumab,9,ZoledronicAcid,318736,Migraine
Outcome,5,Denosumab,9,ZoledronicAcid,4090425,Altered sensation of skin
Outcome,5,Denosumab,9,ZoledronicAcid,313459,Sleep apnea
Outcome,5,Denosumab,9,ZoledronicAcid,136661,Non-toxic nodular goiter
Outcome,5,Denosumab,9,ZoledronicAcid,197672,Urinary incontinence
Outcome,5,Denosumab,9,ZoledronicAcid,4209423,Nicotine dependence
Outcome,5,Denosumab,9,ZoledronicAcid,437390,Hypoxemia
Outcome,5,Denosumab,9,ZoledronicAcid,380094,Carpal tunnel syndrome
Outcome,5,Denosumab,9,ZoledronicAcid,377575,Tinnitus
Outcome,5,Denosumab,9,ZoledronicAcid,253796,Pneumothorax
Outcome,5,Denosumab,9,ZoledronicAcid,4214376,Hyperglycemia
Outcome,5,Denosumab,9,ZoledronicAcid,318556,Epistaxis
Outcome,5,Denosumab,9,ZoledronicAcid,434005,Morbid obesity
Outcome,5,Denosumab,9,ZoledronicAcid,432730,Difficulty speaking
Outcome,5,Denosumab,9,ZoledronicAcid,439147,Amnesia
Outcome,5,Denosumab,9,ZoledronicAcid,253797,Post-inflammatory pulmonary fibrosis
Outcome,5,Denosumab,9,ZoledronicAcid,441417,Incoordination
Outcome,5,Denosumab,9,ZoledronicAcid,433454,Adjustment disorder with mixed emotional features
Outcome,5,Denosumab,9,ZoledronicAcid,376065,Neurologic disorder associated with type 2 diabetes mellitus
Outcome,5,Denosumab,9,ZoledronicAcid,4239682,Chronic phototoxic dermatitis
Outcome,5,Denosumab,9,ZoledronicAcid,30133,Acute laryngitis
Outcome,5,Denosumab,9,ZoledronicAcid,73090,Contusion of foot
Outcome,5,Denosumab,9,ZoledronicAcid,137951,Acquired keratoderma
Outcome,5,Denosumab,9,ZoledronicAcid,257683,Posterior rhinorrhea
Outcome,5,Denosumab,9,ZoledronicAcid,137977,Jaundice
Outcome,5,Denosumab,9,ZoledronicAcid,139850,Acute frontal sinusitis
Outcome,5,Denosumab,9,ZoledronicAcid,376229,Abnormal involuntary movement
Outcome,5,Denosumab,9,ZoledronicAcid,193020,Incomplete emptying of bladder
Outcome,5,Denosumab,9,ZoledronicAcid,376382,Tension-type headache
Outcome,5,Denosumab,9,ZoledronicAcid,137063,Corns and callus
Outcome,6,Denosumab,10,ZoledronicAcid,195562,Hemorrhoids
Outcome,6,Denosumab,10,ZoledronicAcid,318736,Migraine
Outcome,6,Denosumab,10,ZoledronicAcid,4090425,Altered sensation of skin
Outcome,6,Denosumab,10,ZoledronicAcid,313459,Sleep apnea
Outcome,6,Denosumab,10,ZoledronicAcid,136661,Non-toxic nodular goiter
Outcome,6,Denosumab,10,ZoledronicAcid,197672,Urinary incontinence
Outcome,6,Denosumab,10,ZoledronicAcid,4209423,Nicotine dependence
Outcome,6,Denosumab,10,ZoledronicAcid,437390,Hypoxemia
Outcome,6,Denosumab,10,ZoledronicAcid,380094,Carpal tunnel syndrome
Outcome,6,Denosumab,10,ZoledronicAcid,377575,Tinnitus
Outcome,6,Denosumab,10,ZoledronicAcid,253796,Pneumothorax
Outcome,6,Denosumab,10,ZoledronicAcid,4214376,Hyperglycemia
Outcome,6,Denosumab,10,ZoledronicAcid,318556,Epistaxis
Outcome,6,Denosumab,10,ZoledronicAcid,434005,Morbid obesity
Outcome,6,Denosumab,10,ZoledronicAcid,432730,Difficulty speaking
Outcome,6,Denosumab,10,ZoledronicAcid,439147,Amnesia
Outcome,6,Denosumab,10,ZoledronicAcid,253797,Post-inflammatory pulmonary fibrosis
Outcome,6,Denosumab,10,ZoledronicAcid,441417,Incoordination
Outcome,6,Denosumab,10,ZoledronicAcid,433454,Adjustment disorder with mixed emotional features
Outcome,6,Denosumab,10,ZoledronicAcid,376065,Neurologic disorder associated with type 2 diabetes mellitus
Outcome,6,Denosumab,10,ZoledronicAcid,4239682,Chronic phototoxic dermatitis
Outcome,6,Denosumab,10,ZoledronicAcid,30133,Acute laryngitis
Outcome,6,Denosumab,10,ZoledronicAcid,73090,Contusion of foot
Outcome,6,Denosumab,10,ZoledronicAcid,137951,Acquired keratoderma
Outcome,6,Denosumab,10,ZoledronicAcid,257683,Posterior rhinorrhea
Outcome,6,Denosumab,10,ZoledronicAcid,137977,Jaundice
Outcome,6,Denosumab,10,ZoledronicAcid,139850,Acute frontal sinusitis
Outcome,6,Denosumab,10,ZoledronicAcid,376229,Abnormal involuntary movement
Outcome,6,Denosumab,10,ZoledronicAcid,193020,Incomplete emptying of bladder
Outcome,6,Denosumab,10,ZoledronicAcid,376382,Tension-type headache
Outcome,6,Denosumab,10,ZoledronicAcid,137063,Corns and callus
Outcome,7,Denosumab,11,ZoledronicAcid,195562,Hemorrhoids
Outcome,7,Denosumab,11,ZoledronicAcid,318736,Migraine
Outcome,7,Denosumab,11,ZoledronicAcid,4090425,Altered sensation of skin
Outcome,7,Denosumab,11,ZoledronicAcid,313459,Sleep apnea
Outcome,7,Denosumab,11,ZoledronicAcid,136661,Non-toxic nodular goiter
Outcome,7,Denosumab,11,ZoledronicAcid,197672,Urinary incontinence
Outcome,7,Denosumab,11,ZoledronicAcid,4209423,Nicotine dependence
Outcome,7,Denosumab,11,ZoledronicAcid,437390,Hypoxemia
Outcome,7,Denosumab,11,ZoledronicAcid,380094,Carpal tunnel syndrome
Outcome,7,Denosumab,11,ZoledronicAcid,377575,Tinnitus
Outcome,7,Denosumab,11,ZoledronicAcid,253796,Pneumothorax
Outcome,7,Denosumab,11,ZoledronicAcid,4214376,Hyperglycemia
Outcome,7,Denosumab,11,ZoledronicAcid,318556,Epistaxis
Outcome,7,Denosumab,11,ZoledronicAcid,434005,Morbid obesity
Outcome,7,Denosumab,11,ZoledronicAcid,432730,Difficulty speaking
Outcome,7,Denosumab,11,ZoledronicAcid,439147,Amnesia
Outcome,7,Denosumab,11,ZoledronicAcid,253797,Post-inflammatory pulmonary fibrosis
Outcome,7,Denosumab,11,ZoledronicAcid,441417,Incoordination
Outcome,7,Denosumab,11,ZoledronicAcid,433454,Adjustment disorder with mixed emotional features
Outcome,7,Denosumab,11,ZoledronicAcid,376065,Neurologic disorder associated with type 2 diabetes mellitus
Outcome,7,Denosumab,11,ZoledronicAcid,4239682,Chronic phototoxic dermatitis
Outcome,7,Denosumab,11,ZoledronicAcid,30133,Acute laryngitis
Outcome,7,Denosumab,11,ZoledronicAcid,73090,Contusion of foot
Outcome,7,Denosumab,11,ZoledronicAcid,137951,Acquired keratoderma
Outcome,7,Denosumab,11,ZoledronicAcid,257683,Posterior rhinorrhea
Outcome,7,Denosumab,11,ZoledronicAcid,137977,Jaundice
Outcome,7,Denosumab,11,ZoledronicAcid,139850,Acute frontal sinusitis
Outcome,7,Denosumab,11,ZoledronicAcid,376229,Abnormal involuntary movement
Outcome,7,Denosumab,11,ZoledronicAcid,193020,Incomplete emptying of bladder
Outcome,7,Denosumab,11,ZoledronicAcid,376382,Tension-type headache
Outcome,7,Denosumab,11,ZoledronicAcid,137063,Corns and callus
